CRISPR-Cas9: Bacterial immune system-derived DNA precision editing tool. 2020 Nobel Chemistry (Charpentier·Doudna). Ex vivo = cell extraction·edit·re-injection (Casgevy 2023). In vivo = direct patient drug injection (Lonvo-z 2026 L73 first clinical success).

CRISPR-Cas9 is medical revolution core. From 2020 Nobel Chemistry → 2023 first FDA approval (Casgevy) → 2026 first in vivo clinical success (Lonvo-z, L73). Future BRCA·APOE4·autoimmune potential. L73 = molecular receptor → protein degradation → DNA editing evolution.

What it is

CRISPR: Bacterial immune system origin, bacteria remember·block viral DNA, 1987 discovery → 2012 gene editing application, 2020 Nobel Chemistry (Charpentier · Doudna)

Cas9: DNA-cutting nuclease, gRNA targets, precision cut·edit

Action steps: gRNA targets DNA, Cas9 cuts DNA, cell self-repair (NHEJ·HDR), gene expression change

Ex Vivo - Casgevy (2023)

Process: Blood·marrow extraction, lab CRISPR edit, patient re-injection (marrow transplant-like)

Casgevy (Exa-cel·Vertex/CRISPR Therapeutics 2023): First FDA-approved CRISPR drug, sickle cell·beta thalassemia, target BCL11A (fetal hemoglobin activation), price $2.2M, complex·high-cost·marrow transplant-like

In Vivo - Lonvo-z (2026, L73)

Process: Direct drug injection (IV), drug delivery to target organ (liver), CRISPR drug edits intracellular DNA, simple·outpatient·potentially lower cost

Intellia Lonvo-z (2026.4.27, L73): First in vivo CRISPR Phase 3 success, HAE (Hereditary Angioedema), KLKB1 gene target, swelling attacks -87%, complete blockade 60%+, 1-time injection lifelong effect expected

Ex Vivo vs In Vivo

Aspect	Ex Vivo	In Vivo
Method	Extract·edit·re-inject	Direct drug injection
Complexity	High (marrow transplant-like)	Low (outpatient)
Cost	$2M+	$2M+ → ↓ expected
Targets	Blood·marrow cells	Liver·muscle·heart
Recovery	Months	Weeks
Approved	Casgevy (2023)	Lonvo-z Phase 3 (2026)

CRISPR vs Existing Targeted Drugs

Existing drug targets: Receptor blockade (L63 SERM·SARM·anti-CD20), enzyme blockade (L66 BTK fenebrutinib), protein degradation (L67 Veppanu PROTAC)

CRISPR target: Direct DNA editing (permanent), protein → DNA upstream shift, 1-time → lifelong effect

Global CRISPR Trials (2026)

Active: Casgevy (Vertex) ex vivo (2023 first), Lonvo-z (Intellia) in vivo (2026 Phase 3 L73), Beam Therapeutics base editing, Caribou Biosciences cancer immune, Editas Medicine retinal·blood

Prime Editing: Next generation CRISPR, more precise·↓ off-target, 5~10 year clinical

Base Editing: No DNA cut, base change, ↑ safety, A→G·C→T conversion

Ethics·Law

Prohibited: Germline editing (eggs·sperm·embryo) - offspring transmission, designer babies, non-therapeutic modifications

Permitted: Somatic editing (no offspring impact), therapeutic indications, clinical trials (IRB approval)

Global guidelines: WHO advisory committee, UNESCO·OECD, US NIH·NAS, Korean Advanced Regenerative Medicine Law

Korean Implications

Korean CRISPR status: Casgevy MFDS review (2025~), some clinical trials (SNU·Samsung·Asan), Advanced Regenerative Medicine Law (2019) framework, ethics·legal guidelines

Future adoption: Casgevy 2026~2027, Lonvo-z 2028~2030, cost burden ↑·insurance negotiation

Future - Women’s Health CRISPR

5~10 year potential:

BRCA1/2 variants (breast·ovarian): Current: test·prevention·drugs (PARP), future: CRISPR precision editing

APOE4 (Alzheimer·L68): Current: risk factor awareness·lifestyle, future: APOE4 → APOE3 editing possibility

MTHFR (nutrition·pregnancy·L72): Current: active folate, future: enzyme activity restoration

Autoimmune (T-cell editing): Current: immune suppressing drugs, future: T-cell precision editing

Safety·Side Effects

Side effects: Off-target editing, immune reactions (Cas9 protein), tumor risk (theoretical·rare), pregnancy·fetus absolute contraindicated

Monitoring: Long-term tracking (10+ years), follow-up clinical data, side effect reporting system

FAQ

Q. CRISPR really 1-time lifelong effect? A. Animal data + Phase 3 (Lonvo-z) 12+ months. Lifelong effect under verification. Some may need re-injection.

Q. Offspring inheritance? A. Somatic editing (in vivo CRISPR) = no offspring impact. Germline editing = prohibited·offspring transmission possible.

Q. Korean CRISPR availability? A. Casgevy MFDS review. Lonvo-z 2028~2030 expected. Cost burden.

Q. BRCA variant women CRISPR? A. Future potential. Clinical entry 2030~. Current = test·preventive surgery·PARP·lifestyle.

Q. Cost? A. Casgevy $2.2M·Lonvo-z $2M+ expected. Future in vivo cost ↓ potential.

gRNA (guide RNA): Target DNA guide
NHEJ (Non-Homologous End Joining): Cell self DNA repair
HDR (Homology-Directed Repair): Precision repair
Off-target editing: Non-target editing
Prime Editing: Next-gen CRISPR
Base Editing: Base change (no cut)

Conclusion

CRISPR-Cas9 = DNA precision editing medicine. 2020 Nobel Chemistry → 2023 first approval (Casgevy ex vivo) → 2026 first in vivo clinical success (Lonvo-z, L73). L73 = 50 pillars + next step dimension (CRISPR in vivo 2nd axis). Molecular receptor → protein degradation → DNA editing evolution. Korea 2028~2030. Future women BRCA·APOE4·autoimmune potential.

CRISPR-Cas9 Gene Editing — Ex Vivo vs In Vivo Difference